Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for Adenomyosis
NCT07162961Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of nintedanib in adenomyosis, sponsored by Sun Yat-sen University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
adenomyosis
Beyond the preview
Go deeper on NCT07162961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162961.